Clinical trialPhase 1 / Phase 2Completed
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
- Outcome
- Finished, no results posted
- Phase
- Phase 1 / Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 9 October 2019
- Ended
- 20 December 2024
- Enrollment
- 169 participants
- Sites
- 16
- Primary outcomes
- Part A: Incidence of dose limiting toxicity; Part B: Objective response rate; Part C: Incidence of dose limiting toxicity; Part D: Incidence of dose limiting toxicity; Part E: Incidence of dose limiting toxicity
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 24 December 2024
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose as a monotherapy and in combination with chemotherapy for evaluation in these patients.